i think it's a bit of a "tomato, tomato" thing for me there. Pros and cons to both if you watch the videos with clinicians discussing it. Overall, they're indifferent about it, which says it's not much of a differentiator.
Ann: First patient imaged in Phase III AMPLIFY trial, page-16
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.33 |
Change
0.000(0.00%) |
Mkt cap ! $1.400B | |||
| Open | High | Low | Value | Volume |
| $4.31 | $4.44 | $4.20 | $11.74M | 2.723M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $4.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.34 | 132 | 1 |
View Market Depth
| Last trade - 16.16pm 30/07/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |